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K. Eipl, C. Nakabiito, K. Bwogi, M. Motevalli, A. Roots, L. Blagg, and J.B. Jackson
We conducted a population-based, cross-sectional study among 
pregnant women in Kampala, Uganda, to determine ABO and D 
blood types and to determine the percentage who have unexpected 
red blood cell (RBC) antibodies and their specificities. De-
identified blood samples from routine testing of 1001 pregnant 
women at the Mulago Hospital antenatal clinics in Kampala were 
typed for ABO and D and screened for the presence of unexpected 
RBC antibodies with confirmation and subsequent antibody 
identification. Of the 1001 blood samples tested, 48.9 percent, 26.4 
percent, 21.0 percent, and 3.8 percent tested positive for blood 
groups O, A, B, and AB, respectively. Of these samples, 23 (2.3%) 
were negative for D, and 55 (5.5%) showed initial reactivity with at 
least one screening RBC. The RBC antibody screen was repeated 
on these 55 samples, and antibody identification was performed 
at the Johns Hopkins Hospital Blood Bank in Baltimore, 
Maryland. Twenty-one of the 55 samples were confirmed to have 
evidence of agglutination. Nine of the 21 samples demonstrated 
the presence of clinically significant RBC antibodies with anti-S 
being the most common, 8 samples demonstrated the presence 
of benign or naturally occurring antibodies, and 4 had only 
inconclusive reactivity. This study revealed a relatively high 
frequency of D and a low frequency of demonstrable clinically 
significant alloantibodies that may cause hemolytic disease of 
the newborn or hemolytic transfusion reactions among pregnant 
women in Kampala, with anti-S being the most frequent antibody 
specificity. Immunohematology 2012;28:115–7.
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Alloimmunization is the development of antibodies to 
an antigen detected on the cells of another member of the 
same species. Red blood cell (RBC) alloimmunization among 
pregnant women is not infrequent given maternal exposure to 
fetal RBCs having different paternal antigens. The presence 
of these alloantibodies puts the fetus and newborn at risk of 
hemolytic disease1 and places the mother and infant at risk for 
hemolysis if transfusion is needed. D has been found to be the 
Rh system antigen most commonly associated with hemolytic 
disease of the fetus and newborn (HDFN).1 Currently, the 
prevalence of D has not been well studied, nor has the preva-
lence of other unexpected RBC antibodies in pregnant women 
in Kampala, Uganda. One recent study in southwestern Uganda 
found a maternal alloimmunization rate of 2.2 percent,2 which 
is comparable to that found in a similar study conducted in 
Zimbabwe, which indicated a maternal alloimmunization 
rate of 1.7 percent.3 Given the varying prevalence of different 
RBC antigens throughout the world,4 further examination of 
this part of the world is important for clinical care. Therefore, 
we conducted a population-based, cross-sectional study 
to determine the ABO and D blood types among pregnant 
women in Kampala and to determine the percentage who have 
unexpected RBC antibodies and their specificities.
Materials and Methods
Study samples were drawn from 1009 de-identified blood 
samples collected in EDTA anticoagulant left over from routine 
testing at two antenatal clinics at Mulago Hospital. Eight of 
the 1009 total samples were found to have insufficient volumes 
of plasma for all tests to be carried out and were therefore not 
included in the analysis. All remaining samples were tested 
for ABO and D and screened for the presence of unexpected 
RBC antibodies. All blood typing and initial antibody 
screening were performed at the Uganda Core Laboratory of 
the Makerere University-Johns Hopkins University Research 
Collaboration, which provides diagnostic testing for patient 
care and clinical research studies at the Infectious Diseases 
Institute in Kampala. The plasma from all samples showing a 
positive screen for the presence of unexpected antibodies was 
frozen and shipped from the Uganda Core Laboratory to the 
Johns Hopkins Hospital Blood Bank in Baltimore, Maryland, 
for identification of antibody specificities. Shipment of samples 
was done in compliance with local and international regulations, 
by IATA certified laboratory personnel, and under the terms 
of a Materials Transfer Agreement approved by the Uganda 
National Council for Science and Technology as required. Both 
local and Johns Hopkins University institutional review board 
approvals for the study were obtained.
All leftover EDTA samples were stored at 4°C for a 
maximum of 30 days after collection. Blood typing and 
antibody screening were performed using protocols adapted 
from the Johns Hopkins Hospital Blood Bank. Forward and 
reverse ABO and D typing were performed on all samples. 
Forward ABO and D typing was performed using patient 
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RBCs and commercial reagents according to manufacturer’s 
instructions (anti-A, anti-B, anti-D, and Rh control; Immucor, 
Norcross, GA). Reverse ABO grouping was performed using 
sample plasma and commercial group A1 cells and group B 
cells according to manufacturer’s instructions (Referencell2, 
Immucor). Weak D screening was performed on all samples 
testing D negative on immediate spin using monoclonal anti-
IgG and Coombs control cells according to manufacturer’s 
instructions (Immucor). Antibody screening was performed 
on all samples, using a commercial low-ionic-strength 
saline solution (LISS; Ortho Clinical Diagnostics, Raritan, 
NJ), commercial Screening Cell I and Screening Cell II 
(Immucor), and commercial anti-IgG and Coombs control 
cells by manufacturer’s instructions. The plasma of all 
samples that showed a positive reaction at any step during 
the antibody screening procedure was extracted and stored 
at –20°C for later shipment to the Johns Hopkins Hospital 
Blood Bank for confirmation of antibody specificities. At 
Johns Hopkins, samples were retested for unexpected RBC 
antibody identification by the Capture assay on an automated 
instrument (Galileo, Immucor) or by gel test (ID-MTS Gel, 
Ortho Clinical Diagnostics).
Results
A total of 1009 maternal blood samples were collected 
for ABO and D typing, and unexpected RBC antibody testing 
was performed between June and August 2011. Only sex and 
presumed pregnancy status were known, as all samples were 
de-identified before testing. Of the 1001 blood samples tested 
(after 8 had been excluded because they had insufficient 
plasma volume), 48.9 percent, 26.4 percent, 21.0 percent, 
and 3.8 percent tested positive for blood groups O, A, B, and 
AB, respectively, and 23 (2.3%) were negative for D (Table 
1). Fifty-five (5.5%) samples showed initial reactivity with 
at least one screening RBC. The RBC antibody screen and 
identification on these 55 samples were performed at the 
Johns Hopkins Hospital Blood Bank. If sample volume was 
limited, only an antibody identification panel was performed. 
Twenty-one of the 55 samples were confirmed to have 
evidence of reactivity. Nine of the 21 samples demonstrated 
the presence of potentially clinically significant RBC 
antibodies with anti-S being the most frequent (see Table 2), 
8 samples demonstrated the presence of benign or naturally 
occurring antibodies (3 anti-Lea, 2 anti-M, 1 anti-N, and 2 
cold agglutinins), and 4 had inconclusive reactivity.
Discussion
Our study revealed that approximately half of 1001 
pregnant women tested at Mulago Hospital in Kampala were 
group O, and 26.4 percent, 21.0 percent, and 3.8 percent were 
groups A, B, and AB, respectively. Overall, 2.3 percent were 
D–, which is lower than the 7.1 percent found in black blood 
donor populations in the United States5 but comparable to the 
3.6 percent recently reported from southwestern Uganda.2 
The percentage of pregnant women with unexpected RBC 
antibodies was 2.1 percent, which is relatively low given the 
high fertility rate of 6.7 births per woman in Uganda,6 and is 
similar to the 2.2 percent rate found in southwestern Uganda.2 
Pregnant women in Uganda are not routinely typed and 
screened, yet only 1 of 23 D– women demonstrated an anti-D. 
Overall 9 (0.9%) women demon-strated RBC antibodies 
thought to be potentially significant for HDFN. Anti-S was 
the most frequent RBC alloantibody, detectable in 7 (0.7%) 
women, followed by 1 each of anti-D and anti-K. Anti-S was 
also the RBC antibody with the highest prevalence in another 
study among pregnant women in southwestern Uganda at a 
rate of 0.6 percent.2





O 489 (48.9) 14 (2.9) 475 (97.1)
A 264 (26.4) 4 (1.5) 260 (98.5)
B 210 (21.0) 5 (2.4) 205 (97.6)
AB 38 (3.8) 0 (0) 38 (100)











* Total greater than 21 because 5 samples had inconclusive reactivity in 
addition to a specific red blood cell antibody.
†Clinically significant red blood cell alloantibodies.
‡Clinically benign antibodies.
IMMUNOHEMATOLOGY, Volume 28, Number 4, 2012 117
Unexpected red cell antibodies in Uganda
Maternal hemorrhage associated with childbirth is also 
significant in Uganda. A recent study in Uganda reported 
that of 55,803 live births, blood was requested for 185 of 229 
women with severe maternal morbidity.7 However, blood was 
not available for 34 percent of these women as a result of either 
lack of blood in the hospital blood bank, lack of transport to 
the national blood bank, or lack of blood in the national blood 
bank. Although morbidity was not known to be caused by 
difficulty in obtaining compatible blood, antenatal screening 
for RBC antibodies would likely allow timely availability and 
compatibility of blood for transfusion for those women with 
identified clinically significant RBC antibodies.
The implications of our findings are limited given the de-
identified nature of the specimens tested and lack of follow-
up data on the newborns of these women. Consequently, this 
study only showed the presence of demonstrable alloantibody 
as opposed to the percentage of pregnant women with a 
history of alloantibody and those currently demonstrating 
alloantibody. Nevertheless, this study does give the frequency 
and specificities of demonstrable clinically significant 
antibodies that may cause HDFN or require compatible blood 
for transfusion among pregnant women and their neonates 
in Kampala and it demonstrates the feasibility of establishing 
type and screen testing for RBC alloantibody in a health care 
setting.
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